In this section
@article{Zeifman:2023:10.1038/s41598-023-40856-5,
author = {Zeifman, RJ and Kettner, H and Pagni, BA and Mallard, A and Roberts, DE and Erritzoe, D and Ross, S and Carhart-Harris, RL},
doi = {10.1038/s41598-023-40856-5},
journal = {Scientific Reports},
pages = {1--11},
title = {Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences},
url = {http://dx.doi.org/10.1038/s41598-023-40856-5},
volume = {13},
year = {2023}
}
TY - JOUR
AB - Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health care providers and patients. Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin/LSD anecdotally reduces challenging experiences and enhances positive experiences associated with psilocybin/LSD. However, limited research has investigated the acute effects of co-use of MDMA and psilocybin/LSD. In a prospective convenience sample (N = 698) of individuals with plans to use psilocybin/LSD, we examined whether co-use of MDMA with psilocybin/LSD (n = 27) is associated with differences in challenging or positive experiences. Challenging experiences were measured using the Challenging Experiences Questionnaire and positive experiences were measured using the Mystical Experience Questionnaire and single-item measures of self-compassion, compassion, love, and gratitude. Potentially confounding variables were identified and included as covariates. Relative to psilocybin/LSD alone, co-use of psilocybin/LSD with a self-reported low (but not medium–high) dose of MDMA was associated with significantly less intense total challenging experiences, grief, and fear, as well as increased self-compassion, love and gratitude. Co-use of psilocybin/LSD and MDMA was not associated with differences in mystical-type experiences or compassion. Findings suggest co-use of MDMA with psilocybin/LSD may buffer against some aspects of challenging experiences and enhance certain positive experiences. Limitations include use of a convenience sample, small sample size, and non-experimental design. Additional studies (including controlled dose–response studies) that examine the effects and safety of co-administering MDMA with psilocybin/LSD (in healthy controls and clinical samples) are warranted an
AU - Zeifman,RJ
AU - Kettner,H
AU - Pagni,BA
AU - Mallard,A
AU - Roberts,DE
AU - Erritzoe,D
AU - Ross,S
AU - Carhart-Harris,RL
DO - 10.1038/s41598-023-40856-5
EP - 11
PY - 2023///
SN - 2045-2322
SP - 1
TI - Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences
T2 - Scientific Reports
UR - http://dx.doi.org/10.1038/s41598-023-40856-5
UR - https://www.nature.com/articles/s41598-023-40856-5
UR - http://hdl.handle.net/10044/1/106194
VL - 13
ER -
